CEO David Happel emphasized the significance of this milestone, highlighting the promising preclinical data and favorable changes observed in sebum lipid composition in previous trials.

“2024 was a highly productive year for Sagimet, and we’re carrying that momentum into a strong start for 2025,” said David Happel, Chief Executive Officer of Sagimet. “We are pleased to ...

as we advance our second FASN inhibitor into the clinic and expand our therapeutic presence into dermatology,” said David Happel, Chief Executive Officer of Sagimet. “FASN inhibition is a ...

I have known Doug Happel for more than 30 years. His most enduring quality over his long career in public service is his ability to use common sense when dealing with the issues that come before ...